Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses.
Ontology highlight
ABSTRACT: B cells are pivotal regulators of acquired immune responses, and recent work in both experimental murine models and humans has demonstrated that subtle changes in the regulation of B cell function can substantially alter immunological responses. The balance of negative and positive signals in maintaining an appropriate B cell activation threshold is critical in B lymphocyte immune tolerance and autoreactivity. Fc?RIIb (CD32B), the only recognized Fc? receptor on B cells, provides immunoglobulin G (IgG)-mediated negative modulation through a tyrosine-based inhibition motif, which down-regulates B cell receptor-initiated signaling. These properties make Fc?RIIb a promising target for antibody-based therapy. We report the discovery of allele-dependent expression of the activating Fc?RIIc on B cells. Identical to Fc?RIIb in the extracellular domain, Fc?RIIc has a tyrosine-based activation motif in its cytoplasmic domain. In both human B cells and B cells from mice transgenic for human Fc?RIIc, Fc?RIIc expression counterbalances the negative feedback of Fc?RIIb and enhances humoral responses to immunization in mice and to BioThrax vaccination in a human anthrax vaccine trial. Moreover, the FCGR2C-ORF allele is associated with the risk of development of autoimmunity in humans. Fc?RIIc expression on B cells challenges the prevailing paradigm of unidirectional negative feedback by IgG immune complexes via the inhibitory Fc?RIIb, is a previously unrecognized determinant in human antibody/autoantibody responses, and opens the opportunity for more precise personalized use of B cell-targeted antibody-based therapy.
SUBMITTER: Li X
PROVIDER: S-EPMC3982386 | biostudies-literature | 2013 Dec
REPOSITORIES: biostudies-literature
ACCESS DATA